Endomet Biosciences, Inc.
Irvine, CA · Biotech · Private
Small-molecule therapeutic that selectively inhibits a pathway component driving endometrial migration and invasion to treat endometriosis
- Grants
- $7.6M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 2 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $296,838 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $956,480 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $1,115,958 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $2,049,994 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $1,049,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $999,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $999,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Non-hormonal Therapeutic for Endometriosis | $177,500 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2033 | Orthogonal Biologics, Inc. | — | — |
| 2034 | CALIFIA BIO, INC. | — | — |
| 2035 | General Workings Inc. | — | $12M |
| 2036 | Endomet Biosciences, Inc. | — | — |
| 2037 | Apeximmune Therapeutics Inc. | — | — |
| 2038 | VXBIOSCIENCES, INC. | — | — |
| 2039 | RASHMIVU LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Treating Endometriosisapplication
- Compositions And Methods For Treating Endometriosisgranted
- Compositions And Methods For Treating Endometriosisgranted
- Compositions And Methods For Imaging, Diagnosing And Treating Endometriosisapplication
- Compositions And Methods For Imaging And Treating Endometriosisapplication
- Compositions And Methods For Treating Endometriosisapplication
- Compositions And Methods For Treating Endometriosisapplication
- Compositions And Methods For Imaging And Treating Endometriosisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.